Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.
Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Verma C, et al. Among authors: kaewkangsadan v. J Transl Med. 2015 Jun 4;13:180. doi: 10.1186/s12967-015-0535-8. J Transl Med. 2015. PMID: 26040463 Free PMC article.
The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.
Kaewkangsadan V, Verma C, Eremin JM, Cowley G, Ilyas M, Satthaporn S, Eremin O. Kaewkangsadan V, et al. J Immunol Res. 2017;2017:1049023. doi: 10.1155/2017/1049023. Epub 2017 Aug 23. J Immunol Res. 2017. PMID: 28913366 Free PMC article.
Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
Kaewkangsadan V, Verma C, Eremin JM, Cowley G, Ilyas M, Eremin O. Kaewkangsadan V, et al. BMC Cancer. 2018 Feb 2;18(1):123. doi: 10.1186/s12885-018-4044-z. BMC Cancer. 2018. PMID: 29390966 Free PMC article.
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Pivot X, et al. Among authors: kaewkangsadan v. JAMA Oncol. 2022 May 1;8(5):698-705. doi: 10.1001/jamaoncol.2021.8171. JAMA Oncol. 2022. PMID: 35238873 Free PMC article. Clinical Trial.
Primary angiosarcoma of the breast presenting with a benign vascular skin-like lesion and expanding hematoma: a case report of an extremely rare tumor.
Burusapat C, Wongprakob N, Sapruangthong R, Pruksapong C, Kaewkangsadan V, Wongchansom K, Satayasoontorn K. Burusapat C, et al. Among authors: kaewkangsadan v. J Surg Case Rep. 2019 Jul 23;2019(7):rjz223. doi: 10.1093/jscr/rjz223. eCollection 2019 Jul. J Surg Case Rep. 2019. PMID: 31360438 Free PMC article.
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
Pivot X, Manikhas AG, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Deforce F, Cox DG. Pivot X, et al. Among authors: kaewkangsadan v. BMC Cancer. 2023 Jan 31;23(1):112. doi: 10.1186/s12885-023-10574-2. BMC Cancer. 2023. PMID: 36721174 Free PMC article. Clinical Trial.